Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of B-cell lymphoma, showed “promising...

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia

In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia (HCL), three-quarters of participants responded to treatment....

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib led to...

Evaluating FT-2102 in IDH1-Mutated AML or MDS

According to interim data from a first-in-human phase I trial, treatment with FT-2102, a selective inhibitor of mutant IDH1, was tolerable and demonstrated anti-leukemic...

Synthetic Hepcidin Options Safe in Patients With Iron Disorders, But Efficacy Data Still Preliminary

Two studies presented at the 23rd Congress of the European Hematology Association examined the safety and pharmacokinetics of two synthetic hepcidin options for the...

Higher Complete Response Rates With Polatuzumab Vedotin, Bendamustine, and Rituximab Combo in DLBCL

Adding polatuzumab vedotin (an antibodydrug conjugate targeting CD79b-positive cells) to the combination of bendamustine and rituximab (BR) extended survival and increased complete responses (CRs)...

Fostamatinib Increases Hemoglobin Levels in Warm Antibody Autoimmune Hemolytic Anemia

According to findings from a phase II SOAR study presented at the 23rd Congress of the European Hematology Association, twice-daily fostamatinib offered short-term improvement...

Chemotherapy-Free Combination Shows Efficacy in Untreated Follicular Lymphoma

The randomized, global, phase III RELEVANCE trial showed that a regimen of lenalidomide and rituximab (R2) had similar safety and efficacy to a rituximab-based...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.